Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261.
Masakazu NamboTaeko Nishiwaki-OhkawaAkihiro ItoZachary T ArikiYuka ItoYuuki KatoMuhammad YarJacky C-H YimEmily KimElizabeth SharkeyKeiko KanoEmi Mishiro-SatoKosuke OkimuraMichiyo MaruyamaWataru OtaYuko FurukawaTomoya NakayamaMisato KobayashiFumihiko HorioAyato SatoCathleen M CruddenTakashi YoshimuraPublished in: Communications medicine (2024)
ZTA-261, a highly selective and less toxic THRβ agonist, has the potential to be used as a drug for treating diseases related to lipid metabolism.